Raluca Simbotin: How We Care for Complex Patients Is A Measure of Healthcare System Maturity
Raluca Simbotin, Leader of Vaccines Working Group at The Romanian Association of International Medicine Manufacturers (ARPIM), Deputy Chair of AmCham Healthcare Committee, shared on LinkedIn:
”At the National Conference dedicated to rare diseases, I addressed an issue that I consider fundamental: the way we respond to patients with complex needs reflects the maturity, coherence, and humanity of our healthcare system.
Rare diseases may affect smaller patient populations individually, but collectively their impact is significant and far-reaching.
Behind every diagnosis there are often years of uncertainty, repeated consultations, delayed answers, and families navigating a system that is not always designed for complexity.
Pulmonary arterial hypertension is a clear example.The time to diagnosis remains too long.
Access to specialized expertise is uneven. The medical, emotional, and financial burden on patients and families is substantial and ongoing.
We have the knowledge to improve outcomes.
We have the tools to act earlier.
And we have, at this moment, a favorable policy environment to move forward.
At European level, 2026 marks important progress:
- advanced discussions around a European Action Plan for Rare Diseases;
- a stronger emphasis on interoperable registries and meaningful use of health data;
- continued consolidation of European reference networks;
- targeted funding streams for research and innovation.
This European momentum creates opportunity. However, opportunity alone does not generate impact.
Implementation, alignment, and accountability do.
To move forward, we need:
- earlier and more accurate diagnosis, supported by clear referral pathways
- predictable and timely access to innovative therapies
- robust, interoperable data systems to inform policy and measure outcomes
- sustainable funding models that support the full patient journey
Rare diseases challenge systems to operate at their best.
They require coordination across institutions, disciplines, and sectors.
They demand long-term thinking rather than short-term solutions.
Progress will depend on our ability to work together policymakers, clinicians, patient organizations, and industry with clarity of purpose and shared responsibility.
The conversation must continue, but more importantly, it must translate into measurable action.”

Stay updated with Hemostasis Today.
-
Nov 18, 2026, 15:11Vansh Yaduvanshi: Why Compatible Blood Groups Do Not Always Mean Compatible Blood
-
Nov 18, 2026, 14:49Estetrol-Based Contraception in PCOS and Its Effects on Coagulation – RPTH Journal
-
Nov 18, 2026, 14:41Factor V Deficiency: Diagnostic Challenges and the Role of Combined Factor V and VIII Deficiency
-
Nov 18, 2026, 14:29Maxime Dely: When Patient Encounters Become Life Lessons
-
Nov 18, 2026, 14:23Basanta Khatiwada: Advancing Haematology Through Research and Innovation at HAEMATOCON 2026
-
Nov 18, 2026, 14:13Alvin Katumba: Sickle Cell Disease Research Recognised With a 2026 ASH Abstract Achievement Award
-
Nov 18, 2026, 13:34Vincenzo De Angelis: Strengthening Plasma Management and Quality Control in Eastern Europe
-
Nov 18, 2026, 13:34Standardizing Bleeding Outcome Assessment in Hemophilia Clinical Trials – JTH
-
Nov 18, 2026, 13:34Nicolas Gendron: The Ecological Transition in Thrombosis and Haemostasis